Information  X 
Enter a valid email address

Tissue Regenix Group (TRX)


Thursday 16 June, 2022

Tissue Regenix Group

Exercise of Options and Total Voting Rights

RNS Number : 1806P
Tissue Regenix Group PLC
16 June 2022

Tissue Regenix Group plc

("Tissue Regenix", the "Company" or "the Group")


Exercise of Options

And Total Voting Rights


Tissue Regenix Group (AIM:TRX), the regenerative medical devices company, announces that it has received notification for the exercise of options to subscribe for 2,717,391 new ordinary shares in the Company ("Ordinary Shares") at an exercise price of 0.1 pence per Ordinary Share.


The 2,717,391 new Ordinary Shares will rank pari passu with the existing Ordinary Shares and application has been made for these new Ordinary Shares to be admitted to trading on AIM. It is expected that admission will occur at 8:00 a.m. on 21 June 2022.


Total Voting Rights

Following the issue of the 2,717,391 new Ordinary Shares, the Company will have a total of 7,035,794,890 Ordinary Shares in issue. The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.  



For more information:


Tissue Regenix Group plc

David Cocke, Chief Financial Officer

Via Walbrook PR

Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Tel:  +44(0)20 7710 7600 

Ben Maddison / Nick Harland

Walbrook PR Ltd

Tel: +44 (0)20 7933 8780

Alice Woodings / Lianne Applegarth

  [email protected]


About Tissue Regenix (

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or damaged body structures. Current applications address many critical clinical needs in sports medicine, foot and ankle, and wound care.


In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, dental, and ophthalmological surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t